lysine for PMDD
A single anecdote reports markedly reduced PMDD symptoms in one month while taking lysine for a cold sore.
Hypothesized mechanism
Mechanism not yet characterized in the substrate.
This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.
How the score was reached, for this pair
The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 2 of 10 overall, a exploratory reading, from a community rated exploratory in strength.
The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.
Scored for women. Evidence generated in women (female population). (band F1, ×1.00).
Corroboration
Independence (patient accounts): 0 distinct account(s) across 1 thread(s) (author handles unavailable — counting distinct posts).
Rigor
The single report is vague, stating only that the person 'barely felt any PMDD symptoms this month' without dose, timing relative to cycle, duration, or specific symptoms. No measurable detail is provided.
Specificity
The drug (lysine) and outcome (reduced PMDD symptoms) are both clearly named and linked in the quote. However, the link is incidental and the outcome description is generic, so the linkage is weakly specified.
Plausibility
There is no established pharmacological mechanism by which lysine, an amino acid commonly used for cold sores, would alleviate PMDD symptoms. The claim does not fit any known mechanism for this drug-condition pairing.
Consistency
With only one report there is no disagreement, but also nothing to confirm against. The single account is internally coherent but cannot demonstrate cross-report consistency.
Layers not covered for this pair
Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.
More on the sex-specific pharmacokinetics layer and its sources →Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.
More on the cycle-phase layer and its sources →Source evidence · what the pipeline ingested
These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).
Every source below belongs to this signal’s evidence arm, Community reports. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.
- 1noticed I barely felt any PMDD symptoms this month Community report · Reddit ↗
These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.
The primary sources and pipelines this evidence is drawn from →